Almost a third more efficient

Combination of drugs reduced kidney cancer mortality by 27%

Svetlana Maslova, Hi-tech+

In patients with metastatic kidney tumor who received new treatment, it was possible to stop the progression of cancer and significantly reduce the mortality rate. A new study for the first time compares this approach with the standard of first-line treatment and, judging by the results, will be able to replace it in the future.

The team from Dana-Farber Cancer Research Institute presented interim results of the third phase of studies examining the advantages of a combination of three drugs over the standard immunotherapeutic treatment of metastatic kidney cancer — nivolumab and ipilimumab, according to a press release Three-drug combination slows progress of advanced kidney cancer.

To increase the effectiveness of therapy, the scientists added the kinase inhibitor cabozantinib to this tandem. This drug is necessary to suppress several molecular pathways that contribute to the development of cancer. Nivolumab and ipilimumab, in turn, work by blocking immune checkpoints, which allows you to increase the activity of immune cells against the tumor.

The study involved 855 patients who had not previously received any therapy. One group was treated with a standard approach, and the second with a combination of three drugs. Observations showed that exposure to three drugs stopped the progression of cancer and reduced the risk of mortality by 27%.

"The first results provide a clear picture of the effectiveness and safety of the new approach over standard treatment, demonstrating significant benefits of patient survival," commented co—author Tony Choweri.

Currently, the research is ongoing and the final results will be presented later. If successful, the new therapeutic strategy will be able to replace the existing treatment protocol and provide patients with more effective treatment.

Portal "Eternal youth" http://vechnayamolodost.ru